C
eftolozane-tazobactam (C/T) is a new beta-lactam-beta-lactamase inhibitor combination agent that combines a novel oxyimino-cephalosporin (ceftolozane) with an established beta-lactamase inhibitor (tazobactam). C/T was approved by the U.S. Food and Drug Administration in 2014 for the treatment of complicated intra-abdominal infections (cIAI, in combination with metronidazole) and complicated urinary tract infections (cUTI) (1) . In clinical trials, C/T demonstrated noninferiority to meropenem when used in combination with metronidazole for the treatment of cIAIs (2, 3) . Additionally, C/T was noninferior to levofloxacin for the treatment of cUTIs, including pyelonephritis (4), which was mainly attributable to high rates of levofloxacin-resistant isolates among cUTI-causing bacteria (5, check was performed on all isolates. Challenge testing was performed at three clinical sites using 90 frozen stock organisms provided by bioMérieux. All challenge isolates were tested using Etest and BMD. To derive the MIC for BMD in the challenge study, this trial used a voted reference result as the basis for comparison. The voted reference was derived by comparing the BMD results from all three sites for each isolate. The voted reference result was either a consensus result, the best two of three, or a modal value. In situations where all three reference results were the same, the consensus result was used.
Interpretation of results and data analysis. Results from all isolates tested for C/T susceptibility using the Etest and BMD methods were included in the analysis. Essential agreement (EA) was defined as agreement between the two methods Ϯ 1 doubling dilution and was calculated by the Biomath team at bioMérieux. Etest results were rounded up to the nearest dilution that was performed for BMD for this calculation. Categorical agreement (CA) between the Etest and BMD, as well as very major, major, and minor error evaluation, was determined using CLSI breakpoint criteria unless otherwise specified.
RESULTS
Reproducibility of C/T Etest. We used isolates of Enterobacter cloacae (n ϭ 1), Escherichia coli (n ϭ 7), Klebsiella oxytoca (n ϭ 3), Klebsiella pneumoniae (n ϭ 5), and Pseudomonas aeruginosa (n ϭ 9) to evaluate the reproducibility of the Etest at three sites: the Clinical Microbiology Institute (CMI; Portland, OR), the University of CaliforniaLos Angeles (UCLA; Los Angeles, CA) Health System, and Washington University in St. Louis School of Medicine (WU). The MICs of C/T required to inhibit growth of each isolate were compared across sites ( Table 1) , showing that 73/75 (97.3%) isolates tested fell within Ϯ1 doubling dilution of the mode (or the median, if no mode existed).
C/T Etest challenge study. To examine the accuracy of the Etest, we compared MICs derived by C/T Etest to MICs derived by BMD for 51 Enterobacteriaceae and 39 P. aeruginosa strains at CMI, UCLA, and WU (see Table S1 in the supplemental material for details on each isolate). Among the Enterobacteriaceae isolates evaluated, 23/51 (45%) were resistant to C/T by BMD using the CLSI breakpoints (susceptible [S], Յ2/4 g/ml; Table S2 for the specimen type from which each isolate was recovered and the corresponding MIC of each isolate). Per CLSI breakpoints for the Enterobacteriaceae, 56/793 (7.1%) of patient isolates were resistant to C/T by BMD, 728/793 (91.8%) were susceptible, and 9/793 (1.1%) had MICs that fell within the intermediate category ( Table 3 ). The species with the highest percentage of resistant isolates were E. cloacae (8/ Fig. 2A) , with the EA for each species within the Enterobacteriaceae ranging from 93.4% (K. pneumoniae) to 100%. CA for Enterobacteriaceae isolates collectively was 781/793 (98.5%), with the CA for each species within the Enterobacteriaceae ranging from 96.2% (E. cloacae) to 100%. For P. aeruginosa, EA and CA of the C/T Etest versus BMD were 171/173 (98.8%) and 172/173 (99.4%), respectively (Table 3 ; Fig. 2B ). No very major errors were identified in our clinical study. However, two major errors were found: one K. pneumoniae isolate with an Etest MIC of 64 g/ml and a BMD MIC of 0.5 g/ml and one P. rettgeri isolate with an Etest MIC of 8 g/ml and a BMD MIC of 2 g/ml. Eleven minor errors were also identified: 10 from Enterobacteriaceae isolates and 1 from a P. aeruginosa isolate, with no obvious bias toward one pattern of minor error.
We also analyzed the categorical interpretation of our clinical data using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, which are more conservative than CLSI breakpoints for Enterobacteriaceae and do not include an intermediate category (for Enterobacteriaceae, S, Յ1/4 g/ml, and R, Ͼ1/4 g/ml; for P. aeruginosa, S, Յ4/4 g/ml, and R, Ͼ4/4 g/ml). Using EUCAST breakpoints, CA was higher for both Enterobacteriaceae (785/793 [99.0%]) and P. aeruginosa (173/173 [100%]) than CLSI breakpoints. However, more very major (n ϭ 3) and major errors (n ϭ 5) were found when using EUCAST criteria (Table 3) . 
DISCUSSION
C/T is a novel beta-lactam-beta-lactamase inhibitor combination that was developed for the treatment of infections with multidrug-resistant Gram-negative bacteria. In this study, C/T susceptibility testing was performed on a large number of Gramnegative bacterial isolates at multiple study sites across a large geographic distribution in the continental United States. We found that the MIC values derived by the Etest for C/T correlated well with MIC values obtained by BMD for both Enterobacteriaceae and P. aeruginosa, exceeding the Ͼ90% threshold of EA required by the FDA. Additionally, we identified very few categorical and very major errors using CLSI breakpoint criteria for Enterobacteriaceae and P. aeruginosa.
Despite growing interest in the use of C/T by physicians (21) , only a limited number of studies have evaluated the performance of alternatives to BMD for C/T susceptibility testing. Among these studies, a considerable range of performance has been observed for a variety of C/T susceptibility testing devices. For example, a research-use-only (RUO) version of the Etest performed poorly compared to BMD for susceptibility testing of a small number of meropenem-nonsusceptible P. aeruginosa isolates in Michigan (22) , but these data were later questioned when a follow-up to this study suggested favorable performance characteristics for the C/T Etest (Ͻ96% EA and CA) (23) . Although our study did not produce any very major errors in the clinical isolate portion of the study, one very major error was identified in the challenge set study. Interestingly, the isolate for which this error occurred had Etest and BMD results that were internally consistent at each site; however, this isolate had MICs in the susceptible range at one site but MICs that were resistant at the two other sites. Therefore, when the voted BMD reference value was generated, this created a very major error for the one site at which the isolate tested as susceptible. Given the consistency of test results for this isolate within each site, it appears that this error was not due to a failure of the test device but rather an artifact of the data analysis in combination with the possibility of the loss of a resistance plasmid.
Other devices that use gradient diffusion (e.g., Liofilchem MIC test strip) for C/T testing have been shown to have unacceptably high error rates (23) . These discrepancies could reflect the fact that interpretation of MIC results from gradient diffusion devices can be more subjective than BMD results. In addition, the population distribution of many Gram-negative species falls near the breakpoint for this antimicrobial agent, which can be challenging for accurate categorical interpretation. However, various degrees of performance have also been reported for disk diffusion assays for C/T disks (23) (24) (25) . Despite these limitations, in most clinical laboratory settings, C/T susceptibility testing options like gradient diffusion that are more accessible than BMD are critically needed because approximately 10% of infections for which C/T therapy is indicated are caused by a C/T-resistant organism and therefore susceptibility testing is needed to optimize therapy and antimicrobial stewardship (6, 7, 9-17, 24, 26, 27) . Indeed, C/T resistance and treatment failures have already been described and appear to be acquired/mediated via a variety of mechanisms, emphasizing the need for widely accessible phenotypic C/T susceptibility testing (8, 11, 24, (28) (29) (30) .
This study has limitations, including the small number of isolates for some of the specific species evaluated and the lack of resistant isolates for some species tested. The strengths of this study include reference BMD as a reference method, standardization of preparation of the BMD panels, the large number of isolates evaluated, and the multicenter nature of the study.
In conclusion, testing a large number of clinical strains from different geographic regions within the United States, we found that the bioMérieux C/T Etest is a reproducible and accurate method for C/T susceptibility testing of Enterobacteriaceae and P. aeruginosa.
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